title: CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
authors: Münster, Germany.
authors: Nicholas
authors: N
authors: Schwab
authors: Münster, Germany.
authors: Tilman
authors: T
authors: Schneider-Hohendorf
authors: Münster, Germany.
authors: Heinz
authors: H
authors: Wiendl
mesh_terms: D006801:Humans; D015415:Biomarkers; D007577:JC Virus / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000175:diagnosis / Q000188:drug therapy; D000069442:Natalizumab / Q000627:therapeutic use; D019041:L-Selectin / Q000032:analysis
chemical_list: D015415:Biomarkers; D000069442:Natalizumab; C546935:SELL protein, human; D019041:L-Selectin